HCW Biologics Inc. Common Stock
HCWBStock
$4.06−83.56%52W
Market Cap$6.48M
P/E—
Div yield—
Beta2.38
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-52.13%
Price vs S&P 500 (4W)-37.73%
VGM Score44.68
Market Capitalization$6.48M
Earnings Surprise History
Q1 262.22est. -0.45
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HCWBHCW Biologics Inc. Common Stock | B | F | C | $4.06 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies to treat age-related diseases by targeting chronic inflammation. The company uses its proprietary TOBI discovery platform to generate two lead candidates: HCW9218, which neutralizes growth factors and stimulates immune cells, and HCW9302, which activates regulatory T cells to reduce inflammation. This approach targets the inflammation-aging link to potentially extend healthspan across multiple indications.